Get access

Etanercept use for psoriasis in Taiwan: a case series study


  • Funding: None.

  • Conflicts of interest: TF-T has conducted clinical trials or received honoraria for serving as a consultant for Wyeth Pharmaceuticals (now Pfizer Pharmaceuticals), Serono International SA (now Merck Serono International), UniPharma/Biogen Idec and Janssen-Cilag Pharmaceuticals, and has received a speaker’s fee from Abbott Laboratories.

Tsen-Fang Tsai, md
Department of Dermatology
National Taiwan University Hospital
7 Chung-Shan South Road
Taipei 100


Background  The reported efficacy and safety of some biologic agents for psoriasis vary between Caucasians and Asians. Few reports of etanercept exist in psoriasis patients within the Asia-Pacific region.

Objectives  The study aims to report our clinical experience of etanercept in the treatment of patients with moderate-to-severe psoriasis in Taiwan.

Methods  A retrospective analysis of 59 patients with moderate-to-severe psoriasis who received etanercept was conducted in a tertiary referral center.

Results  Etanercept therapy resulted in a reduction of mean Psoriasis Area and Severity Index (PASI) of 47% at week 12 and 61% at week 24. After 12 weeks of treatment, 48%, 26%, and 3.4% of the patients achieved at least PASI50, 75 and 90 response, respectively. At week 24, the proportion of patients achieving at least PASI50, 75 and 90 response was 59%, 37%, and 14%, respectively. Etanercept efficacy in achieving PASI75 improvement was, however, lower than that reported in previous pivotal placebo-controlled trials. No cases of active tuberculosis, viral hepatitis or malignancies were observed during the observation period.

Conclusion  Our case series demonstrated the efficacy and safety of etanercept for the management of moderate-to-severe psoriasis in Taiwan.